Adjusting Radiotherapy Mid-Treatment for Throat Cancer Patients
Tests mid-treatment MRI-guided radiotherapy adjustment in adults with throat cancer receiving chemoradiation.
Plain-language title generated from the registry record
Registry title: Adaptive RadioTherapy for OroPharynx Cancer
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT04901234
- Record updated
- 24 August 2026
- Original description
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.Read full original descriptionShow less
Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Inclusion: Age ≥18 years; Ability to provide written informed consent; Stage T3-T4N0-3 as per AJCC 8th edition; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx; Planned for curative radiotherapy +/- chemotherapy; For females of child-bearing age, a negative pregnancy test; Patients treated with induction chemotherapy can be included if they have residual tumor in place.
Exclusion: Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer; Previous surgery of the HNC region (except for incisional or excisional biopsies); Connective tissue disease; Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy; Pregnancy or breastfeeding; Patients with contra-indications to MRI will be excluded.